Skip to main content
MRNA
NASDAQ Life Sciences

Moderna的mCOMBRIAX，全球首个流感-新冠组合疫苗，获得欧盟营销授权

feedReported by Access Newswire
Sentiment info
Positive
Importance info
8
Price
$53.09
Mkt Cap
$20.967B
52W Low
$22.28
52W High
$59.55
Market data snapshot near publication time

summarizeSummary

Moderna已获得欧盟委员会对其mCOMBRIAX的营销授权，这是一种针对50岁及以上个体的mRNA组合疫苗，针对流感和COVID-19。该批准具有极大的意义，因为mCOMBRIAX是全球首个获得此类许可的流感加新冠组合疫苗，在整个欧盟和相关国家均有效。该新产品加强了Moderna的呼吸系统产品组合，并提供了一个至关重要的新收入机会，尤其是在公司最近的10-K报告显示收入下降和产品线瓶颈的背景下。基于强大的3期试验结果，该授权允许Moderna简化高风险成人的免疫接种。投资者现在将关注公司在国家监管和准入程序中的进展，以评估疫苗的市场推出和销售潜力。

在该公告发布时，MRNA的交易价格为$53.09，交易所为NASDAQ，所属行业为Life Sciences，市值约为$209.7亿。 52周交易区间为$22.28至$59.55。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Access Newswire。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article